Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Obesity 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Motor Activity 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Colorectal Neoplasms 1Cardiotoxicity 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Whole-Body Irradiation 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5Melphalan 4Etoposide 4Cytarabine 4Azacitidine 4AP 1903 reagent 4ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Cyclosporine 3venetoclax 2pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Exercise Test × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡